Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rLP2086 + Repevax
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
rLP2086 + Repevax is a co-administration of two vaccines in adolescents and young adults. Bivalent rLP2086 (marketed as Trumenba) is a recombinant, bivalent protein-based vaccine against *Neisseria meningitidis* serogroup B that contains subfamily A and B factor H binding proteins (fHBPs), inducing protective bactericidal antibodies. Repevax is a combination vaccine containing diphtheria toxoid, tetanus toxoid, acellular pertussis antigens (pertussis toxoid, filamentous hemagglutinin, pertactin, and fimbriae types 2 and 3), and inactivated poliovirus types 1, 2, and 3, which induces immunity against these pathogens. Clinical studies showed that concomitant administration is immunologically noninferior and well tolerated, triggering robust immune responses to all target antigens[1][2][3].
- Brand names
- Trumenba
- Other names
- bivalent rLP2086 + DTaP/IPVbivalent rLP2086 + Repevax
02
Targets
fHbp (Factor H-binding protein)PRN (Pertactin)FHA (Filamentous hemagglutinin)CFH (Complement factor H)Poliovirus type 1 D-antigenPoliovirus type 3 D-antigenFIM2/FIM3 (Fimbriae types 2 and 3)TT (Tetanus toxoid)
Beyond the preview
Go deeper on rLP2086 + Repevax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rLP2086 + Repevax.